Compare MRT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | ALXO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 205.9M |
| IPO Year | 2021 | 2020 |
| Metric | MRT | ALXO |
|---|---|---|
| Price | $1.95 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.58 | $3.50 |
| AVG Volume (30 Days) | 46.0K | ★ 1.0M |
| Earning Date | 08-08-2018 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $1.02 |
| 52 Week High | $2.75 | $2.66 |
| Indicator | MRT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 50.59 |
| Support Level | $1.99 | $1.90 |
| Resistance Level | $2.29 | $2.17 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 92.73 | 47.92 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.